| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Paul Peter Tak
Also a director
Chief Executive Officer, President and Director
|
66 |
Since 2020
6 years
|
Not stated | |
|
Charles Schoch
Chief Financial Officer, Treasurer and Secretary
|
41 | Not stated | 2021 | |
|
Francesca Barone
Chief Scientific Officer
|
49 | Not stated | 2020 | |
|
W. Garrett Nichols
Chief Medical Officer
|
57 | Not stated | Not stated | |
|
Seshu Tyagarajan
Chief Technology Officer
Title from the Form 4 dated Aug 17, 2026
|
58 | Not stated | Not stated | |
|
Maria Ostrovsky
General Counsel
Title from the Form 4 dated Nov 3, 2026
|
Not stated | Not stated | Not stated | |
|
Mark E. Sims
Chief Commercial Officer
Title from the Form 4 dated Jul 6, 2026
|
Not stated | Not stated | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 29, 2026 · updated by the 8-K of Sep 10, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Paul B. Manning
Board chair
|
70 |
2018
8 years
|
Not stated |
Compensation Committee
|
Liquidia Corporation | $130,546 | |
|
Paul Peter Tak, M.D., Ph.D., FMedSci
CEO
|
66 |
2020
6 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Edward J. Benz, Jr.
|
79 |
2017
9 years
|
Not stated |
Nominating and Corporate Governance Committee · Chair
|
None stated | $103,546 | |
|
Maha Radhakrishnan, M.D.
|
56 |
2025
1 year
|
Not stated |
Audit Committee
|
Entrada Therapeutics, Inc. | $158,346 | |
|
Renee Gaeta
|
45 |
2022
4 years
|
Not stated | None stated | None stated | $103,046 | |
|
Gary J. Nabel, M.D., Ph.D.
|
72 |
2022
4 years
|
Not stated |
Nominating and Corporate Governance Committee
|
Siga Technologies, Inc. | $99,546 | |
|
Joseph C. Papa, R.Ph., M.B.A.
|
70 |
2022
4 years
|
Not stated |
Compensation Committee
|
Prometheus Biosciences, Inc. | $101,810 | |
|
Nicoletta Loggia, Ph.D., R.Ph.
|
58 |
2023
3 years
|
Not stated | None stated | None stated | $107,019 | |
|
Christopher Martell
|
47 |
2018
8 years
|
Not stated |
Nominating and Corporate Governance Committee
|
None stated | $114,546 | |
|
Diem Nguyen, Ph.D.
|
54 |
2021
5 years
|
Not stated |
Compensation Committee
|
Verrica Pharmaceuticals Inc. | $104,310 | |
|
Martine Zimmermann
Joined Sep 8, 2026
|
- | - | Independent | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 29, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...